Pseudoprogression in Non–Small Cell Lung Cancer Upon Immunotherapy: Few Drops in the Ocean?

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.12.011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.01-56 Hyperprogression and Pseudoprogression in Patients With Non-Small Cell Lung Cancer on Checkpoint Blocking Immunotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Latest Immunotherapy Methods in Non-Small Cell Lung Cancer Treatment

Juntendo Medical Journal
2019English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy

The Lancet
Medicine
2019English

Immunotherapy in Extensive Small Cell Lung Cancer

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2019English

Potential Role of Immunotherapy in Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Immunotherapy in Non-Small Cell Lung Cancer: The Past, the Present, and the Future

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy – Authors' Reply

The Lancet
Medicine
2019English

Review of Checkpoint Immunotherapy for the Management of Non-Small Cell Lung Cancer

ImmunoTargets and Therapy
AllergyImmunology
2018English

18f-Fet PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non–Small Cell Lung Cancer

Clinical Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy